According to the literature, the current first-line treatment for metastatic ccRCC is sunitinib malate, an oral multitargeted tyrosine kinase inhibitor with antitumor and anti-angiogenic activity that targets VEGFR, KIT, and PDGFR. This evidence concerns the gene PDGFRB and nonpapillary renal cell carcinoma.